摘要
目的分析洛铂联合依托泊苷治疗广泛期小细胞肺癌的近期疗效及不良反应。方法分析我院近1年收治的广泛期小细胞肺癌患者,23例给予洛铂联合依托泊苷治疗(观察组);另20例给予顺铂联合依托泊苷治疗(对照组)。比较两组近期疗效及不良反应。结果观察组、对照组总有效率78.26%、75.00%(P>0.05);观察组、对照组平均无进展生存期(6.1±0.5)个月、(5.3±0.7)个月(P>0.05);观察组不良反应粒细胞减少4.35%,消化道反应4.35%、贫血4.35%;对照组粒细胞减少10.00%、腹泻5.00%、血小板减少5.00%。结论洛铂联合依托泊苷治疗广泛期小细胞肺癌与顺铂联合依托泊苷方案疗效相近,安全、耐受性好。
Objective To analyze the curative effects and adverse reactions of lobaplatin combined with etoposide in treat- ment of patients with extensive stage small cell lung cancer. Methods Analyzed the extensive stage small cell lung cancer patients admitted in our hospital in recent one year. 23 cases were treated by lobaplatin combined with etoposide （the ob- servation group）; the other 20 patients were given eisplatin etoposide treatment （the control group）. The recent curative elk fect and adverse reaction were compared between the two groups. Results The total effective rate of the observation group and the control group was 78.26% and 75.00% （P 〉 0.05）; the median progression-free survival of the observation group and the control group was 6.1＋0.5 and 5.3＋0.7 months （P 〉 0.05）; the neutropenia of the observer group was 4.35%, the gastrointestinal reactions was 4.35%, the anemia was 4.35%; the neutropenia of the control group was 10.00%, the diarrhea was 5.00%, the thrombocytopenia was 5.00%. Conclusion Lobaplatin plus etoposide treatment of extensive stage small cell lung cancer in combination with cisplatin etoposide program has similar efficacy, and it is safe and well tolerated.
出处
《中国现代医生》
2012年第30期72-73,共2页
China Modern Doctor
基金
河北省自然科学基金(c2009001262)
唐山科学技术研究与发展计划卫生临床研究项目(11150205A-12)
关键词
洛铂
依托泊苷
小细胞肺癌
近期疗效
不良反应
Lobaplatin
Etoposide
Small cell lung cancer
Short term efficacy
Adverse reactions
